ATIM-18. SURVIVAL OF SUBJECTS WITH RECURRENT GLIOBLASTOMA RECEIVING INTRA-TUMORAL ADMINISTRATION OF IL-12 MANAGED WITH LOW-DOSE DEXAMETHASONE

Ad-RTS-hIL-12 (Ad) is a novel gene therapy, conditionally expressing IL-12 via the RheoSwitch Therapeutic System® (RTS®) gene switch under control of an oral activator ligand, veledimex (V). We previously reported results from 51 subjects (NCT02026271 and NCT03679754) describing biological activity...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Lukas, Rimas, Chiocca, Ennio, Kurz, Sylvia, Yu, John, Landolfi, Joseph, Rao, Ganesh, Buck, Jill, Demars, Nathan, Smith, Amy, Miao, John, Zhou, John, Wang, Yunxia, Gelb, Arnold, Cooper, Laurence
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Adult Clinical Trials–Immunologic
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847372/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.018
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi